All insightsSeptember 23, 2026

Why Clearance Is Easy and Payment Is Hard: The 2026 State of Medtech Market Access

FDA authorization opens the U.S. market, but coding, coverage, payment and hospital adoption determine whether a medical device can build a sustainable business. Here is what changed in 2026.

FDA authorization feels like the finish line because it is visible, technical and binary. A 510(k) is cleared, a De Novo request is granted or a PMA is approved. The commercial system that follows is less tidy. A medical device may still need a usable billing code, favorable coverage, adequate payment and a hospital willing to fund implementation.

That is why clearance can be easier to plan than payment. Regulatory pathways have defined submissions and review standards. Market access depends on several institutions answering different questions, often on different calendars and with different evidence expectations.

The central lesson of 2026 is not that FDA clearance has become easy. It is that authorization alone does not establish reimbursability, affordability or adoption.

Four gates, four different questions

FDA asks whether a device meets the applicable standard for marketing: substantial equivalence for many 510(k)s, reasonable assurance of safety and effectiveness for PMAs, or a favorable benefit-risk profile and special controls for De Novo devices.

Coding asks how the service, procedure or item will be described on a claim. Coverage asks whether a payer considers it reasonable and necessary for a defined population. Payment asks how much the payer will pay and whether the amount sits inside a bundled rate or receives separate payment. Hospital adoption asks whether the local clinical and economic case is strong enough to justify spending.

CMS's Guide for Medical Technology Companies separates coding, coverage and payment for exactly this reason. They interact, but success at one gate does not guarantee success at the next.

Coding is the language of payment, not proof of payment

A device may fit an existing CPT, HCPCS or ICD-10-PCS code, require a new code, or be considered part of an existing service. Each outcome changes the commercial strategy. An existing code can speed claims submission, but it may describe a broader service whose payment does not cover the new technology's cost. A new code can improve visibility, but a code by itself does not compel coverage or create adequate payment.

Teams should map coding while clinical evidence is still being generated. The expected site of care, operator, procedure and claim type influence which coding system matters. A product used in an inpatient stay faces a different payment architecture from software used in a physician office or an outpatient diagnostic service.

Coverage asks for evidence that matters to the payer

FDA evidence and payer evidence overlap, but they are not identical. A payer may ask whether outcomes apply to its population, whether the comparator reflects current practice, whether benefits persist, and whether the technology changes utilization or total cost. A study designed only to meet a regulatory endpoint may leave those questions unanswered.

Medicare coverage can be established nationally, locally or through an existing policy. Coverage with Evidence Development can link access to participation in a qualifying study when important evidence gaps remain. Commercial payers conduct their own technology assessments and may reach different decisions at different times.

The practical implication is simple: build a parallel evidence plan. Add endpoints that support coverage and adoption, such as downstream utilization, patient-relevant outcomes, workflow effects and resource use, without compromising the regulatory study.

RAPID is the major 2026 development—but it is targeted

In 2024, CMS finalized the Transitional Coverage for Emerging Technologies pathway, or TCET, for certain FDA-designated Breakthrough Devices. It aimed to coordinate benefit-category, coding and payment reviews and reach a national coverage determination within six months after FDA authorization for accepted technologies.

In 2026, CMS and FDA introduced the proposed Regulatory Alignment for Predictable and Immediate Device pathway, known as RAPID. The proposal focuses on eligible Class II and Class III Breakthrough Devices and moves CMS engagement earlier, so evidence expectations for Medicare can be considered during development rather than after authorization.

RAPID is important because it addresses the sequencing problem: manufacturers often learn too late that evidence sufficient for FDA is not sufficient for coverage. But it is not a universal reimbursement route. Eligibility is narrow, implementation details matter, and coverage still does not answer every coding, payment or local adoption question.

Payment adequacy is its own problem

Even a covered device can be commercially difficult if payment is bundled into a rate established around older technology. Hospitals then compare the incremental product cost with any savings they can capture inside the same episode.

For inpatient care, the New Technology Add-on Payment program can provide temporary additional payment for qualifying technologies. In hospital outpatient care, transitional pass-through payment and new-technology APC mechanisms can address certain new products or services.

These mechanisms are temporary and criterion-specific. They should be treated as bridges, not permanent business models. A manufacturer still needs a plan for the payment environment after the temporary period ends.

Hospital market access begins where reimbursement ends

Positive payer policy does not force a hospital to adopt. A value analysis committee, service line, finance team and IT organization may still evaluate local patient volume, contract terms, staffing, implementation and budget impact. The device must compete against other clinical and capital priorities.

This is where a national reimbursement strategy becomes a local value story. A hospital needs to know whether payment is incremental or bundled, which department receives it, when cash is collected, and whether clinical savings fall inside its budget horizon. A national coverage policy is useful; a hospital-specific model is actionable.

A better sequence for medtech companies

Begin with the intended care pathway and site of service, not the FDA submission alone. Map the likely code, coverage mechanism, payment unit and hospital buyer before pivotal study endpoints are locked.

Seek early conversations with FDA and CMS when the product and program are eligible. For other products, engage coding experts, payers and provider finance leaders early enough to change the evidence plan.

Build three connected dossiers: a regulatory dossier proving safety and performance; a payer dossier establishing patient benefit and evidence relevance; and a provider dossier translating adoption into workflow, budget impact and measurable outcomes.

Model uncertainty explicitly. Show the business case under existing coding, delayed coverage, bundled payment and temporary add-on scenarios. The objective is not to predict one perfect launch path, but to know which decisions could break it.

The strategic takeaway

Clearance creates permission to market. Coding creates a claimable description. Coverage creates eligibility for payment. Payment policy sets the amount and mechanism. Hospital adoption turns those pieces into use.

In 2026, RAPID offers a promising effort to align regulatory and Medicare evidence earlier for a targeted group of Breakthrough Devices. It does not erase the need for a market-access strategy. The strongest companies will design regulatory, reimbursement and provider evidence together, long before the FDA decision date.

Explore the medical device market access guide for a practical view of coding, coverage and payment, and use MedTech Compass to compare reimbursement and adoption conditions across 25+ markets.